Samsung Bioepis has filed three petitions for IPR challenging Genentech patents related to the use of Herceptin^® (trastuzumab): IPR2017-01958, challenging U.S. Patent 6,627,196; IPR2017-01959 challenging U.S. Patent 7,371,379; and IPR2017-01960 challenging U.S. Patent 7,892,549.  Samsung Bioepis concurrently filed motions for joinder with Hospira’s petitions challenging the same patents (IPR2017-00804, IPR2017-00805, and IPR2017-00737), and which were instituted by the Board.